U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287995) titled 'A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors' on Dec. 15.
Brief Summary: Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then attack the tumor cells in people with solid tumors. ASP2998 will either be given by itself, or given together with one or more of standard cancer treatments pembrolizumab, carboplatin, and enfortumab vedotin.
This is an early development study to collect information about ASP2998 in people with solid tumors. In this...